Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure
- 2 January 2019
- journal article
- research article
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 270 (1) , 71-82
Abstract
The efficacy of aripiprazole therapy and the risk of adverse reactions are influenced by substantial inter-individual variability in aripiprazole metabolizing capacity. In vitro studies assigned the potential role in aripiprazole metabolism to CYP2D6 and CYP3A enzymes; therefore, the association between the steady-state aripiprazole plasma concentrations and patients’ CYP2D6 and CYP3A statuses (CYP2D6, CYP3A4, and CYP3A5 genotypes, and CYP3A4 expression) and/or co-medication with CYP function modifying medications has been investigated in 93 psychiatric patients on stable aripiprazole therapy. The patients’ CYP2D6 genotype had a major effect on aripiprazole plasma concentrations, whereas contribution of CYP3A genotypes and CYP3A4 expression to aripiprazole clearance were considered to be minor or negligible. The role of CYP3A4 expression in aripiprazole metabolism did not predominate even in the patients with nonfunctional CYP2D6 alleles. Furthermore, dehydroaripiprazole exposure was also CYP2D6 genotype-dependent. Dehydroaripiprazole concentrations were comparable with aripiprazole levels in patients with functional CYP2D6 alleles, and 35% or 22% of aripiprazole concentrations in patients with one or two non-functional CYP2D6 alleles, respectively. The concomitant intake of CYP2D6 inhibitors, risperidone, metoprolol, or propranolol was found to increase aripiprazole concentrations in patients with at least one wild-type CYP2D6*1 allele. Risperidone and 9-hydroxy-risperidone inhibited both dehydrogenation and hydroxylation of aripiprazole, whereas metoprolol and propranolol blocked merely the formation of the active dehydroaripiprazole metabolite, switching towards the inactivation pathways. Patients’ CYP2D6 genotype and co-medication with CYP2D6 inhibitors can be considered to be the major determinants of aripiprazole pharmacokinetics. Taking into account CYP2D6 genotype and co-medication with CYP2D6 inhibitors may improve the outcomes of aripiprazole therapy.Keywords
Funding Information
- National Research, Development and Innovation Office (NKFIH/OTKA K104459, NKFIH/OTKA K104738, VEKOP-2.3.3-15-2017-00014)
This publication has 58 references indexed in Scilit:
- Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and ExpressionThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?BMC Psychiatry, 2011
- The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamineEuropean Journal of Clinical Pharmacology, 2011
- Pharmacokinetics and metabolism update for some recent antipsychoticsExpert Opinion on Drug Metabolism & Toxicology, 2011
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed DrugDrug Metabolism and Disposition, 2008
- AripiprazoleDrugs, 2004
- AripiprazoleCNS Drugs, 2002
- Managing Antipsychotic-Induced Acute and Chronic AkathisiaDrug Safety, 2000